ArticleScientific reports2022
Adaptation of the gut pathobiont Enterococcus faecalis to deoxycholate and taurocholate bile acids.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 31 citations in OpenAlex.
- The Nexus of Gut Microbiome, Microbial Metabolites, and Colonization Resistance Against Enteric Pathogens.Biomolecules · 2026Review
- Trending ileal microbiome dysbiosis over time as an early assessment of intestinal transplant rejection risk.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026Article
- Functional redundancy of translation-associated factors masks the role of YebC2 in Enterococcus faecalis.Folia microbiologica · 2026Article
- Gut microbiome features associated with vancomycin-resistant Enterococcus acquisition in intensive care unit patients.Annals of clinical microbiology and antimicrobials · 2026Article
- Gut-liver axis molecular mechanisms in alcohol-associated liver disease.Alcohol (Fayetteville, N.Y.) · 2026Review
- Harnessing Microbiome-Mediated and Macrophage-Driven Mechanisms for Oral Wound Healing.Microorganisms · 2026Review
- Gut Microbiota Differences in Down Syndrome Are Most Pronounced in Childhood and Diminish With Age.International journal of microbiology · 2026Article
- Gut microbiota dysbiosis: Pathogenic drivers and emerging phage-based therapeutics.AIMS microbiology · 2026Review
- Impact of Lipophilicity-Tuning on the Antimicrobial Activity of a Series of β-Face-Expanding Bile Acid Derivatives.BioMed research international · 2026Article
- Shared metabolism between a bacterial and fungal species that reside in the human gut.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Deoxycholic Acid Mitigates Necrotic Enteritis Through Selective Inhibition of Pathobionts and Enrichment of Specific Lactic Acid Bacteria.Pathogens (Basel, Switzerland) · 2025Article
- Enhancing Resistance toNutrients · 2025Article
- Article
- Potentially probiotic NPL 1334 strain of Enterococcus durans benefits rats with diet-induced hypercholesterolemia.BMC biotechnology · 2025Article
- Evaluating the antibacterial efficacy of bee venom against multidrug-resistant pathogenic bacteria: Escherichia coli, Salmonella typhimurium, and Enterococcus faecalis.World journal of microbiology & biotechnology · 2025Article
- Antimicrobial activity of Monascus purpureus-derived red pigments against Salmonella typhimurium, Escherichia coli, and Enterococcus faecalis.AMB Express · 2025Article
- Bacteriological Identification, Characterization and Changes of Feces Microbiome in Prostate Cancer Patients Undergoing Radiotherapy.Cancer management and research · 2025Article
- Microbiome characterization of a pre-Hispanic man from Zimapán, Mexico: Insights into ancient gut microbial communities.PloS one · 2025Article
- Antibacterial Potential of Honeybee Venom andBiology · 2024Article
- Gut Microbiota as Predictive Biomarker for Chronic Heart Failure in Patients with Different Nutritional Risk.Journal of cardiovascular translational research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enterococcus faecalis is a natural inhabitant of the human gastrointestinal tract. This bacterial species is subdominant in a healthy physiological state of the gut microbiota (eubiosis) in adults, but can become dominant and cause infections when the intestinal homeostasis is disrupted (dysbiosis). The relatively high concentrations of bile acids deoxycholate (DCA) and taurocholate (TCA) hallmark eubiosis and dysbiosis, respectively. This study aimed to better understand how E. faecalis adapts to DCA and TCA. We showed that DCA impairs E. faecalis growth and possibly imposes a continuous adjustment in the expression of many essential genes, including a majority of ribosomal proteins. This may account for slow growth and low levels of E. faecalis in the gut. In contrast, TCA had no detectable growth effect. The evolving transcriptome upon TCA adaptation showed the early activation of an oligopeptide permease system (opp2) followed by the adjustment of amino acid and nucleotide metabolisms. We provide evidence that TCA favors the exploitation of oligopeptide resources to fuel amino acid needs in limiting oligopeptide conditions. Altogether, our data suggest that the combined effects of decreased DCA and increased TCA concentrations can contribute to the rise of E. faecalis population during dysbiosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.